QCM
CRL icon

Qsemble Capital Management’s Charles River Laboratories CRL Stock Holding History

Qsemble Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Sell
2,645
-701
-21% -$130K 0.03% 365
2025
Q4 		$667K Buy
+3,346
New +$607K 0.06% 337
2024
Q3 		– Sell
-1,187
Closed -$245K – 412
2024
Q2 		$245K Sell
1,187
-2,485
-68% -$563K 0.05% 374
2024
Q1 		$995K Buy
+3,672
New +$877K 0.22% 180

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Qsemble Capital Management's CRL Position: Q1 2026 in Review

Qsemble Capital Management reduced its Charles River Laboratories (CRL) stake by 21% in Q1 2026, selling an estimated $130K and leaving 2,645 shares worth $456K. The position accounts for 0.03% of the portfolio, ranked #365.

Qsemble Capital Management first reported a position in CRL in Q1 2024 and has held it in 4 quarters since. The position peaked at $995K in Q1 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Qsemble Capital Management held 2,645 shares of Charles River Laboratories worth $456K as of Q1 2026.
  • Qsemble Capital Management sold 701 Charles River Laboratories shares in Q1 2026, an estimated $130K.
  • Charles River Laboratories made up 0.03% of Qsemble Capital Management's portfolio in Q1 2026, its #365 holding.
  • Qsemble Capital Management first reported a position in Charles River Laboratories in Q1 2024 and has held it in 4 quarters since.
  • Qsemble Capital Management's Charles River Laboratories position peaked at $995K in Q1 2024.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.